

Health Services Immunization Form

DUE DATES: August 1st (Fall admission)

December 15th (Spring admission)

Legal Name: _____ **Preferred Name** _____ **Pronouns** _____

Date of Birth: ____/____/____ **Biologic Sex Assigned at Birth** _____ **Student ID:** _____

SECTION A:
REQUIRED VACCINES

Meningococcal

1-2 doses

Maryland law requires residential students to receive at least one dose of a quadrivalent conjugate meningococcal vaccine at age 16 or older.

Date: ____/____/____ ☐ Menactra (MenACWY-D) ☐ Menveo (MenACWY-CRM) ☐ MenQuadfi (MenACWY-TT)
Booster: ____/____/____ ☐ Menactra (MenACWY-D) ☐ Menveo (MenACWY-CRM) ☐ MenQuadfi (MenACWY-TT)

☐ Waiver requested (if checked, you must complete the **Meningococcal Vaccine Waiver** form)

Measles/Mumps/Rubella

2 doses

MMR Dose #1: Date ____/____/____ MMR Dose #2: Date ____/____/____

OR

Measles Dose #1: Date ____/____/____ Measles Dose #2: Date ____/____/____
Mumps Dose #1: Date ____/____/____ Mumps Dose #2: Date ____/____/____
Rubella Dose #1: Date ____/____/____ Rubella Dose #2: Date ____/____/____

Special considerations:

*Students born before 1957 without evidence of immunity should be vaccinated.

*Acceptable evidence of immunity includes documentation of MMR vaccine, laboratory evidence of immunity (blood titer), or history of the disease.

*In a measles outbreak, those born before 1957 without other evidence of immunity should be brought up to date on their MMR vaccination.

Blood titers, as applicable:

Measles lab confirmation of positive immunity: Date ____/____/____

Mumps lab confirmation of positive immunity: Date ____/____/____

Rubella lab confirmation of positive immunity: Date ____/____/____

**If the titers are negative or equivocal, 2 doses of MMR at least 28 days apart are needed. No repeat titer is required after the MMR vaccine series.*

☐ Waiver requested (if checked, you must complete the **Measles, Mumps, and Rubella Vaccine Waiver** form)

**SECTION B:
RECOMMENDED VACCINES**

COVID-19

One dose of an updated COVID-19 vaccine is recommended for everyone, including people who have received a prior COVID-19 vaccine, or have had COVID-19, and people with long COVID.

Date: ____/____/____ ☐ Moderna ☐ Pfizer-BioNTech ☐ Novavax

Additional dose(s), if applicable:

Date: ____/____/____ ☐ Moderna ☐ Pfizer-BioNTech ☐ Novavax Date: ____/____/____ ☐ Moderna ☐ Pfizer ☐ Novavax

Hepatitis A

2 doses

Dose #1: Date ____/____/____ ☐ Havrix ☐ Vaqta

Dose #2: Date ____/____/____ ☐ Havrix ☐ Vaqta

Hepatitis B

2-3 dose series

Dose #1: Date ____/____/____ ☐ Heplisav-B ☐ Engerix-B ☐ PreHevbrio ☐ Rebombivax HB

Dose #2: Date ____/____/____ ☐ Heplisav-B ☐ Engerix-B ☐ PreHevbrio ☐ Rebombivax HB

Dose #3: Date ____/____/____ ☐ Engerix-B ☐ PreHevbrio ☐ Rebombivax HB

Hepatitis A and B, Combined (Twinrix)

3- 4 dose series

Dose #1: Date ____/____/____

Dose #2: Date ____/____/____

Dose #3: Date ____/____/____

Dose #4: Date ____/____/____

Human Papillomavirus

2-3 dose series

Dose #1: Date ____/____/____ ☐ Gardasil 9 ☐ Gardasil 4 ☐ Cervarix

Dose #2: Date ____/____/____ ☐ Gardasil 9 ☐ Gardasil 4 ☐ Cervarix

Dose #3: Date ____/____/____ ☐ Gardasil 9 ☐ Gardasil 4 ☐ Cervarix

Influenza

One dose of an updated influenza vaccine annually

Date: ____/____/____

Meningococcal, Serotype B

☐ Bexsero (MenB-4C) 2-3 dose series

OR

☐ Trumenba (MenB-FHbp) 2-3 dose series

Dose #1: Date ____/____/____

Dose #1: Date ____/____/____

Dose #2: Date ____/____/____

Dose #2: Date ____/____/____

Dose #3: Date ____/____/____

Dose #3: Date ____/____/____

If administering a pentavalent vaccine, a combination of dosing scenarios is possible depending on intervals between dosing; check off only what applies to this patient:

☐ Penbraya (MenACWY-TT/MenB-FHbp)

☐ Trumenba

☐ any MenACWY vaccine (name: _____)

Dose #1: Date ____/____/____

Date: ____/____/____

Date: ____/____/____

Dose #2: Date ____/____/____

SECTION B:
RECOMMENDED VACCINES (continued)

MPOX (Jynneos)

2 doses

Dose #1: Date ____/____/____

Dose #2: Date ____/____/____

Pneumococcal

1-2 doses

Date: ____/____/____

☐ Vaxneuvance

☐ Prevna20

☐ Capvaxive

☐ Pneumovax23

**If Vaxneuvance was used, it should have been followed by a dose of Pneumovax23 at least 1 year after* Date: ____/____/____

Polio

Were the primary 4-dose series of inactivated polio vaccine (IPV) completed? ☐ Yes ☐ No

Date of last dose: ____/____/____

Tetanus/Diphtheria/Pertussis

Were the primary 4-dose series completed? ☐ Yes ☐ No

Date of last booster: ____/____/____

If tetanus ONLY was received (which is uncommon), date of last booster: ____/____/____

Varicella

2 doses

Dose #1: Date ____/____/____

☐ Varivax

☐ ProQuad (MMR + varicella)

Dose #2: Date ____/____/____

☐ Varivax

☐ ProQuad (MMR + varicella)

Special considerations:

Acceptable evidence of immunity can be demonstrated by being born in the U.S. before 1980, having a history of the disease, receiving 2 prior doses of varicella vaccine, or providing documentation of an antibody level consistent with immunity.

Blood titer, as applicable:

Varicella lab confirmation of positive immunity: Date ____/____/____

**If the titer is negative or equivocal, the varicella series must be repeated with doses at least 4 weeks apart. No titer is required after the varicella vaccine series is complete.*

SECTION C:
REQUIRED TUBERCULOSIS SCREENING

The following questions are to be completed by the students:

1. Have you ever had close contact with people who are known or suspected of having active TB disease?
☐ Yes ☐ No
2. Were you born in one of the countries or territories listed below that have a high incidence of active TB disease? (If yes, CIRCLE the countries or territories listed in the table on page 4.)
☐ Yes ☐ No
3. Have you resided in or traveled to one or more of the countries or territories listed above for one to three months or more, in total? (If yes, CIRCLE the countries or territories listed in the table on page 4.)
☐ Yes ☐ No

4. Have you been a resident, volunteer, and/or employee of high-risk congregate settings (e.g., correctional facilities, long-term care facilities, and homeless shelters)?
☐ Yes ☐ No
5. Have you been a volunteer or health care worker who served clients who are at an increased risk for active TB disease?
☐ Yes ☐ No
6. Have you ever been a member of any of the following groups that may have an increased incidence of inactive TB infection or active TB disease: *medically underserved, low-income, or using drugs or alcohol*?
☐ Yes ☐ No

2025 High-Incidence Country List for TB Disease

Afghanistan	China	Guatemala	Madagascar	Pakistan	Timor-Leste
Algeria	China, <i>Hong Kong</i>	Guinea	Malawi	Palau	Togo
Angola	SAR	Guinea-Bissau	Malaysia	Panama	Tunisia
Anguilla	China, <i>Macao</i>	Guyana	Maldives	Papua	Turkmenistan
Argentina	SAR	Haiti	Mali	New Guinea	Tuvalu
Armenia	Colombia	Honduras	Marshall	Paraguay	Uganda
Azerbaijan	Comoros	India	Islands	Peru	Ukraine
Bangladesh	Congo	Indonesia	Mauritania	Philippines	Uruguay
Belarus	Congo	Iraq	Mexico	Qatar	Uzbekistan
Belize	(<i>Democratic</i>	Kazakhstan	Micronesia	Romania	Vanuatu
Benin	<i>Republic of</i>)	Kenya	(Federal States	Russian	Venezuela
Bhutan	Côte d'Ivoire	Kiribati	of)	Federation	(Bolivarian
Bolivia	Djibouti	Korea	Moldova	Rwanda	Republic of)
(<i>Plurinational</i>	Dominican	(Democratic	(Republic of)	Sao Tome &	Viet Nam
<i>State of</i>)	Republic	People's	Mongolia	Principe	Yemen
Bosnia &	Ecuador	Republic of)	Morocco	Senegal	Zambia
Herzegovina	El Salvador	Korea	Mozambique	Sierra Leone	Zimbabwe
Botswana	Equatorial Guinea	(Democratic	Myanmar	Singapore	
Brazil	Eritrea	Republic of)	Namibia	Solomon	
Brunei	Eswatini	Korea (Republic	Nauru	Islands	
Darussalam	Ethiopia	of)	Nepal	Somalia	
Burkina Faso	Fiji	Kyrgyzstan	Nicaragua	South Africa	
Burundi	Gabon	Lao People's	Niger	Sri Lanka	
Cabo Verde	Gambia	Democratic	Nigeria	Sudan	
Cambodia	Georgia	Republic	Niue	Suriname	
Cameroon	Ghana	Lesotho	Northern	Tajikistan	
Central African	Greenland	Liberia	Mariana	Tanzania (United	
Republic	Guam	Libya	Islands	Republic of)	
Chad		Lithuania		Thailand	

If you answered YES to any of the above questions, *proceed to page 5.*

**St. Mary's College of Maryland requires that you receive TB testing before the start of your first enrolled term.
The significance of any travel exposure should be reviewed with your health care provider.**

If you answered NO to all the above questions, no further testing or action is required.

The following test(s) are to be completed by a healthcare provider if the student answered YES to any of the screening questions:

Tuberculosis Skin Test (TST)

Date of Test: ____/____/____

Results: ☐ Negative

☐ Positive

OR

Interferon Gamma Release Assay (IGRA):

(QuantiFERON-TB Gold Plus (QFT-Plus) **OR** T-Spot TB)

Date of Test: ____/____/____

Results: ☐ Negative

☐ Positive

Chest X-ray:

(required if current or previous TST or IGRA test is positive)

Date of X-ray: ____/____/____

Results: ☐ Normal

☐ Abnormal

Bacteriologic examinations of sputum specimens, if indicated:

Date of test(s): _____

Results: _____

**TB blood tests (and TB skin tests) should not be performed on people who have written documentation of a previous positive TB test result (TB blood test or TB skin test) or treatment for TB disease. Most people who have a positive TB test result will continue to have a positive test result. Additional TB blood tests will probably not contribute to medical care, regardless of the result.*

I reviewed the information provided on all five (5) pages with the patient and verified that this information is accurate to the best of my knowledge.

Print Provider Name: _____ Provider Signature: _____ Date: _____

Provider Address: _____

Phone: _____

OFFICIAL PROVIDER STAMP:

STUDENT: Once signed by your healthcare provider, upload this form along with the Demographic and Consent form, Health Questionnaire form, and any Vaccination Waiver form(s) into your SMCM Medicat Health Record:

[Health Services: New Student Information](http://www.smcm.edu/health-services/new-student-information)

www.smcm.edu/health-services/new-student-information

****This is the ONLY immunization record that will be accepted****